By Marie Rosenthal
An increasing number of patients with hepatitis C virus infection are being denied a lifesaving treatment by their insurance provider, according to a poster (Sa1501) presented today at Digestive Disease Week, in Chicago.
Trio Health, which has collected real-world data on HCV patients since the launch of the direct-acting antiviral agents (DAAs) in late 2013, said earlier reviews of the data showed that Medicaid restrictions were the primary driver behind